The use of low molecular weight heparin-pluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway

Biomaterials

Volumn 32, Issue 5, 2011, Pages 1438-1445

  Lee, Ju Hee ^a   Lee, Hyunseung ^a   Joung, Yoon Ki ^b   Jung, Kyung Hee ^a   Choi, Jong Hoon ^b   Lee, Don Haeng ^a   Park, Ki Dong ^b   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

Author keywords

Anti Fibrotic agent; DMN; Liver fibrosis; Low molecular weight heparin pluronic nanogel (LHP); TGF Smad

Indexed keywords

ADVERSE EFFECT; ANTI-FIBROTIC AGENT; ANTICOAGULANT ACTIVITIES; ASPARTATES; BODY WEIGHT; COLLAGEN TYPE I; DMN; EXTRACELLULAR MATRICES; FIBROTIC AREA; LIVER FIBROSIS; LOW-MOLECULAR WEIGHT HEPARINS; MATRIX METALLOPROTEINASE-2; METALLOPROTEINASES; NANOGELS; PLURONIC F-127; PLURONICS; PROTEIN EXPRESSIONS; SMAD SIGNALING; SMOOTH MUSCLE ACTINS; TISSUE INHIBITOR; TRANSFORMING GROWTH FACTORS; WEIGHT LOSS;

AMINO ACIDS; COAGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER; MOLECULAR WEIGHT; NANOSTRUCTURED MATERIALS; POLYSACCHARIDES; SIGNALING; TISSUE;

WEIGHING;

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ANTICOAGULANT AGENT; ANTIFIBROTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; COLLAGEN TYPE 1; GELATINASE A; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EXTRACELLULAR MATRIX; GENE EXPRESSION; LIVER FIBROSIS; NONHUMAN; PLURONIC NANOGEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

RATTUS;

EID: 78649743982     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.023     Document Type: Article

References (47)

1. Latella G., Vetuschi A., Sferra R., Catitti V., D'Angelo A., Zanninelli G., et al. Targeted disruption of Smad 3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int 2009, 29(7):997-1009.
2. Hu P.F., Chen H., Zhong W., Lin Y., Zhang X., Chen Y.X., et al. Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol 2009, 51(1):102-113.
3. Du S.L., Pan H., Lu W.Y., Wang J., Wu J., Wang J.Y. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007, 322(2):560-568.
4. Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007, 117(3):539-548.
5. Friedman S.L. Liver fibrosis - from bench to bedside. J Hepatol 2003, 38(Suppl. 1):S38-S53.
6. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115(2):209-218.
7. Pinzani M., Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001, 21(3):397-416.
8. Lotersztajn S., Julien B., Teixeira-Clerc F., Grenard P., Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005, 45:605-628.
9. Parsons C.J., Takashima M., Rippe R.A. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007, 22(Suppl. 1):S79-S84.
10. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., et al. Targeted disruption of SMAD 3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999, 18(5):1280-1291.
11. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 2004, 279(15):15167-15176.
12. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126(3 Suppl):188S-203S.
13. Quader M.A., Stump L.S., Sumpio B.E. Low molecular weight heparins: current use and indications. J Am Coll Surg 1998, 187(6):641-658.
14. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006, 114(2):79-102.
15. Frizelle S., Schwarz J., Huber S.A., Leslie K. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. Am J Pathol 1992, 141(1):203-209.
16. Shi J., Hao J.H., Ren W.H., Zhu J.R. Effects of heparin on liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2003, 9(7):1611-1614.
17. Abdel-Salam O.M., Baiuomy A.R., Ameen A., Hassan N.S. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005, 51(1):59-67.
18. Li W., Zhang J., Huang Q., Zhu H., Zhang X. Long-term administering low anticoagulant activity heparin can lessen rat hepatic fibrosis induced by either CCl(4) or porcine serum injection. Hepatol Res 2006, 36(2):115-123.
19. Douketis J.D., Ginsberg J.S., Burrows R.F., Duku E.K., Webber C.E., Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996, 75(2):254-257.
20. Park K., Kim Y.S., Lee G.Y., Park R.W., Kim I.S., Kim S.Y., et al. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res 2008, 25(12):2786-2798.
21. Lee Y.K., Kim S.K., Lee D.Y., Lee S., Kim C.Y., Shin H.C., et al. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J Control Release 2006, 111(3):290-298.
22. Kim S.K., Lee D.Y., Lee E., Lee Y.K., Kim C.Y., Moon H.T., et al. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release 2007, 120(1-2):4-10.
23. Lee E., Kim Y.S., Bae S.M., Kim S.K., Jin S., Chung S.W., et al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 2009, 124(12):2755-2765.
24. Khattak S.F., Bhatia S.R., Roberts S.C. Pluronic F127 as a cell encapsulation material: utilization of membrane-stabilizing agents. Tissue Eng 2005, 11(5-6):974-983.
25. Park K.M., Bae J.W., Joung Y.K., Shin J.W., Park K.D. Nanoaggregate of thermosensitive chitosan-pluronic for sustained release of hydrophobic drug. Colloids Surf B Biointerfaces 2008, 63(1):1-6.
26. Tsukamoto H., Matsuoka M., French S.W. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990, 10(1):56-65.
27. Lee Y., Nam J.H., Shin H.C., Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 2001, 104(25):3116-3120.
28. Ikejima K., Takei Y., Honda H., Hirose M., Yoshikawa M., Zhang Y.J., et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122(5):1399-1410.
29. Jamall I.S., Finelli V.N., Que Hee S.S. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981, 112(1):70-75.
30. Seifert W.F., Bosma A., Hendriks H.F., van Leeuwen R.E., van Thiel-de Ruiter G.C., Seifert-Bock I., et al. Beta-carotene (provitamin A) decreases the severity of CCl4-induced hepatic inflammation and fibrosis in rats. Liver 1995, 15(1):1-8.
31. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150(1):76-85.
32. Benyon R.C., Iredale J.P., Goddard S., Winwood P.J., Arthur M.J. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996, 110(3):821-831.
33. Preaux A.M., Mallat A., Nhieu J.T., D'Ortho M.P., Hembry R.M., Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999, 30(4):944-950.
34. Benyon R.C., Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001, 21(3):373-384.
35. Hemmann S., Graf J., Roderfeld M., Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007, 46(5):955-975.
36. Liu J., Tan H., Sun Y., Zhou S., Cao J., Wang F. The preventive effects of heparin-superoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice. Mol Cell Biochem 2009, 327(1-2):219-228.
37. Iredale J.P., Goddard S., Murphy G., Benyon R.C., Arthur M.J. Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci (Lond) 1995, 89(1):75-81.
38. Knittel T., Mehde M., Kobold D., Saile B., Dinter C., Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 1999, 30(1):48-60.
39. Iredale J.P., Murphy G., Hembry R.M., Friedman S.L., Arthur M.J. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest 1992, 90(1):282-287.
40. Herbst H., Wege T., Milani S., Pellegrini G., Orzechowski H.D., Bechstein W.O., et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997, 150(5):1647-1659.
41. Iredale J.P., Benyon R.C., Arthur M.J., Ferris W.F., Alcolado R., Winwood P.J., et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996, 24(1):176-184.
42. Iredale J.P., Benyon R.C., Pickering J., McCullen M., Northrop M., Pawley S., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102(3):538-549.
43. Knittel T., Mehde M., Grundmann A., Saile B., Scharf J.G., Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 2000, 113(6):443-453.
44. Yoshiji H., Kuriyama S., Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 2002, 23(6):348-356.
45. Corpechot C., Barbu V., Wendum D., Kinnman N., Rey C., Poupon R., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35(5):1010-1021.
46. Ankoma-Sey V., Wang Y., Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000, 31(1):141-148.
47. Prosser C.C., Yen R.D., Wu J. Molecular therapy for hepatic injury and fibrosis: where are we?. World J Gastroenterol 2006, 12(4):509-515.